A Case of Congenital Central Hypoventilation Syndrome with PHOX2B Gene Mutation in a Korean Neonate

Kyoung-Ah Kwon1, Su-Eun Park1, Shin-Yun Byun1, Shiny-Young Kim2, and Sang-Hyun Hwang2

Departments of Pediatrics1 and Laboratory Medicine2, Pusan National University School of Medicine, Busan, Korea

Received: 24 June 2009
Accepted: 21 October 2009

Address for Correspondence:
Su-Eun Park, M.D., Department of Pediatrics, Pusan National University Children's Hospital, Beomeori, Mulgeum-eup, Yangsan 626-770, Korea
Tel: +82.55-360-2180, Fax: +82.55-360-2181
E-mail: psepse@naver.com

DOI: 10.3346/jkms.2010.25.8.1237

INTRODUCTION

Congenital central hypoventilation syndrome (CCHS) is a rare autosomal dominant disorder of the autonomic nervous system (ANS) characterized by an abnormal autonomic ventilatory response to progressive hypercapnia and sustained hypoxemia. Most patients present with hypoventilation or apnea during the neonatal period, typically while asleep and/or awake without any other associated diseases such as cardiac, pulmonary, neuromuscular or brain stem abnormalities (1, 2). A rare association with Hirschsprung disease (Haddad syndrome) was first described in 1978; five cases of Haddad syndrome have been reported in Korea (3-7). It is because of the association with aganglionosis of the bowel that a number of candidate genes have been considered.

A common pathogenesis involving neural crest-derived cell lineages has been suggested (8). Studies of genes pertinent to the early embryologic development of the ANS include the mammalian achaetescute homolog-1 (MASH1), bone morphogenic protein-2 (BMP2), engrailed-1 (EN1), TLX3, endothelin converting enzyme-1 (ECE1), endothelin-1 (EDN1), PHOX2A, and PHOX2B among 67 probands with CCHS. No disease-defining mutations were identified in MASH1, BMP2, EN1, TLX3, ECE1, EDN1, or PHOX2A. However, 97% of patients with CCHS have been found to be heterozygous for the exon 3 polyalanine expansion mutation identified previously in PHOX2B (9). PHOX2B has been mapped to chromosome 4p12 and consists of 3 exons. It encodes a highly conserved paired-like homeo box transcription factor of 314 amino acids linked to the RET-GDNF signaling pathway. The DNA binding homeo domain is encoded by exon 2, whereas exon 3 encodes two short and stable polyalanine tracts of 9 and 20 residues (2). Expression studies performed in mice and humans have shown that this is a master regulatory gene, crucial for the normal development of the peripheral and central ANS (10-12). We herein report a case of CCHS in a Korean patient that was confirmed during the neonatal period by the identification of PHOX2B mutations.

CASE REPORT

Clinical history

A 3,070 g male at 41 weeks gestation age was born in our hospital via cesarean section because of cephalopelvic disproportion on July 26, 2007. His mother was healthy during her pregnancy (gravida 1, para 0). The boy was well at birth, with Apgar scores of 7 and 9 at 1 and 5 min, respectively. He repeatedly had apnea with cyanosis and desaturation, noticed from the 15 hr after birth, and improved by awakening. He sometimes developed seizures when the PaCO2 accumulated, which needed supportive care with mechanical ventilation. No abnormalities were noted on the chest radiograph, EEG (Fig. 1), MRI of the brain, echocardiography and screening blood tests for metabolic disease. Symptoms of respiratory failure with slow and irregular respiratory effort, cyanosis and seizures due to hypercapnia appeared during sleep but not during wakefulness (Fig. 2). The diagnosis of CCHS was suspected. Peripheral blood samples...
for the gene study were obtained from the patient and his mother at the age of 33 days with consented document of the family.

The infant could not weaned from mechanical ventilation due to sleep apnea. He had a tracheostomy and was discharged with a home mechanical ventilation. At the age of 27 months, he is healthy except still ventilator-dependent during sleep. The patient achieved normal growth and development.

**DNA preparation**

Blood (4 mL) was collected into an EDTA tube from the patient and his mother. Genomic DNA was obtained using a Puregene reagent kit (Gentra, Minneapolis, MN, USA) according to the manufacturer’s instructions.

**Genotyping of PHOX2B polyalanine repeat sequence**

The PHOX2B exon 3 region coding for the polyalanine repeat was amplified with primer pair 5'–CCAGGTCCCAATCCCAAC-3' (forward) and 5’-GAGCCCAGCCTTGTCCAG-3' (reverse) (Fig. 3). The PCR reactions were carried out using 0.25 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA) in a total volume of 25 μL, containing 50 ng of genomic DNA, 0.5 μM primers, 2.5 mM MgCl2, and 0.2 mM dNTPs. The amplification was performed with an initial denaturation at 95°C for 10 min followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 57°C for 30 sec, and extension at 72°C for 30 sec. Final extension was at 72°C for 10 min. After electrophoresis of the PCR products on a 4% denaturing polyacrylamide gel, the allele repeat number was determined by comparison of bands to known size standards (232 bp for normal 20 repeat allele) (9).

**Sequence analysis of PHOX2B exons 2 and 3 region**

PHOX2B exons 2 and 3 were amplified with primer pairs noted in Table 1. The amplification of exon 2 was carried out using 1.25 U AmpliTaq Gold polymerase (Applied Biosystems) in a total volume of 25 μL, containing 50 ng of genomic DNA, 0.5 μM of primers, 1 mM MgCl2, and 0.2 mM dNTPs. The amplification of exon 3 was performed using the GC-RICH system (Roche Molecular Biochemicals, Indianapolis, IN, USA) for its high GC content. The amplification for both exons was performed with an initial denaturation at 95°C for 8 min, followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 62°C for 1 min, and extension at 72°C for 45 sec. Final extension was at 72°C for 10 min. The PCR products were column-purified and sequenced on an Applied Biosystems 3130 genetic analyzers (Applied Biosystems).

**Results of mutation**

A polyalanine repeat expansion mutation was identified in the baby with CCHS. He carried a normal allele, as well as the expanded alleles (Fig. 4). The expanded alleles contained insertions of 18 bp DNAs for coding 6 alanines. An extra band with a

---

**Table 1. Primer sequences* for the CCHS PHOX2B gene**

| Exon | Forward primers | Reverse primers |
|------|----------------|-----------------|
| 1    | GACCTCAAGAAGCTCTCA | AATTACCCCTGCCAACATC |
| 2    | CTGCGTTAGACGGCTATT | ACAGCGAAGCGGAAATCCAGT |
| 3    | ACCCTAACGGCTGCTTCT | ACAATAGCTGGGCTACCC |

*Cited from Weese-Mayer et al. (9).
DISCUSSION

CCHS was suspected in the present case based on following findings: 1) hypoventilation during sleep with no increase of respiratory frequency following severe desaturation, 2) onset of symptoms during the first day of life and a history of recurrent hypercapnic respiratory failure, and 3) absence of primary neuromuscular, lung or cardiac disease, or an identifiable brainstem lesion.

CCHS occurs in association with Hirschsprung disease (Haddad syndrome) by 15-20% frequency, tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) by 3%, and growth hormone deficiency by <1% (13). Korean patients with CCHS combined with Hirschsprung disease have been reported based on clinical symptoms without genetic analysis (3-7). The occurrence of CCHS and Hirschsprung disease suggests a common molecular pathogenesis involving defects of one or more genes that control the development of neural crest-derived cell lineages. This patient did not have any other abnormalities but will be monitored for a malignancy of the ANS in the future.

The clinical outcome of CCHS is variable. Infants with CCHS may present with hypoventilation of variable severity, ranging from complete apnea during sleep, severe hypoventilation during wakefulness, to mild hypoventilation during sleep (9, 14). The patient reported here, required a tracheostomy and used ahome mechanical ventilator in the pressure-support mode. The patient became ambulatory while awake and intermittently required ventilator support during sleep only.

The role of genes in the pathogenesis of CCHS has been widely investigated. Several studies have shown that a heterozygous mutation in PHOX2B is sufficient to cause CCHS, and this has confirmed its autosomal dominant inheritance pattern with incomplete penetrance (9, 10, 15-19). This gene is known to code for a highly conserved transcription factor and plays a key role in the development of ANS reflex circuits in mice, hence the association with CCHS. Mapping of the PHOX2B mutation in chromosome 4p12 has been detected in approximately 97% of patients with CCHS, and the majority of expanded alleles contained 25-27 polyalanine repeats (9). This patient showed the same PHOX2B mutation with expanded alleles containing 20 polyalanine repeats. Weese-Mayer et al. (9) suggested that the length of the PHOX2B polyalanine repeat mutation is associated with number of ANS symptoms and that there is also a significant association between the number of repeats in the mutations and the ventilation support required. The current patient had a relatively small number of polyalanine repeats compared to previous cases and required intermittent ventilator support during sleep, which was for less than 12 hr a day.

Clinically, evaluation of the PHOX2B expansion could be used as a predictive test for CCHS, therefore it might be particularly useful for parents of a child with CCHS and grown children with CCHS. In addition, prenatal testing can then be used to predict the severity of affected individuals in subsequent pregnancies. The identification of mutations in PHOX2B is important for the differential diagnosis in children with confusing symptoms such as asphyxia, prematurity, bronchopulmonary dysplasia, and neonatal seizures, and may lead to improved treatment options for children with CCHS (9). This is the first report of CCHS confirmed by a PHOX2B mutation in Korea.

REFERENCES

1. Gozal D. Congenital hypoventilation syndrome: An update. Pediatr Pulmonol 1998; 26: 273-82.
2. Or SF, Tong MF, Lo FM, Law CW, Miu TY, Trochet D, Lam TS. PHOX2B mutations in three Chinese patients with congenital central hypoventilation syndrome. Chin Med J (Engl) 2006; 119: 1749-52.
3. Choi JH, Oh JH, Kim JH, Koh DK, Hong SC. Congenital central hypoventilation syndrome combined with Hirschsprung disease diagnosed in the neonatal period. Korean J Pediatr 2006; 49: 446-50.
4. Lee MK, Kim JS, Park SJ, Kim KS, Kim IK, Yoon CH, Kim KM. A Case of Haddad Syndrome. Korean J Pediatr Gastroenterol Nutr 2005; 8: 252-6.
5. Hwang IO, Lee ES. A case of Ondine’s curse with Hirschsprung disease. J Korean Soc Neonatol 2004; 11: 72-6.
6. Jung SE, Kim DY, Kim KH, Lee SC, Park KW, Kim WK. The neurocristopathy in a newborn with congenital central hypoventilation syndrome, Hirschsprung’s disease and ganglioneuroblastoma. J Korean Assoc Pediatr Surg 1999; 5: 146-51.
7. Ahn YM, Choi HR, Lee HI, Dong ES. A case of congenital central hypoventilation syndrome (ondine’s curse) with Hirschsprung’s disease. Pediatr Allergy Respir Dis 1993; 3: 113-20.
8. Rohrer T, Trachsel D, Engelcke G, Hammer J. Congenital central hypoventilation syndrome associated with Hirschsprung’s disease and neuroblastoma: case of multiple neurocristopathies. Pediatr Pulmonol 2002; 33: 71-6.
9. Weese-Mayer DE, Berry-Kravis EM, Zhou L, Maher BS, Silvestri JM, Curran ME, Marazita ML. Idiopathic congenital central hypoventilation syndrome. Pediatr Pulmonol 2000; 30: 300-306.
syndrome: analysis of genes pertinent to early autonomic nerve system embryologic development and identification of mutations in PHOX2b. Am J Med Genet A 2003; 123A: 267-78.

10. Amiel J, Laudier B, Attié-Bitach T, Trang H, de Pontual L, Gener B, Trochet D, Etchevers H, Ray P, Simonneau M, Vekemans M, Munnich A, Gautier C, Lyonnet S. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Gene 2003; 33: 459-61.

11. Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF. The homeobox gene Phox2B is essential for the development of autonomic neural crest derivatives. Nature 1999; 399: 366-70.

12. Benailly HK, Lapierre JM, Laudier B, Amiel J, Attié T, De Blois MC, Vekemans M, Romana SP. PMX2B, a new candidate gene for Hirschsprung’s disease. Clin Genet 2003; 64: 204-9.

13. Trang H, Dehan M, Beaufils F, Zaccaria I, Amiel J, Gautier C; French CCHS Working Group. The French Congenital Central Hypoventilation Syndrome Registry: general data, phenotype, and genotype. Chest 2005; 127: 72-9.

14. Coleman M, Boros SJ, Huseby TL, Brennomb WS. Congenital central hypoventilation syndrome: a report of successful experience with bilateral diaphragmatic pacing. Arch Dis Child 1980; 55: 901-3.

15. Trochet D, O’Brien LM, Gozal D, Trang H, Nordenskjöld A, Laudier B, Svensson PJ, Uhrig S, Cole T, Niemann S, Munnich A, Gautier C, Lyonnet S, Amiel J. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet 2005; 76: 421-6.

16. Sasaki A, Kanai M, Kijima K, Akaba K, Hashimoto M, Hasegawa H, Otaki S, Koizumi T, Kusuda S, Ogawa Y, Tuchiya K, Yamamoto W, Nakamura T, Hayasaka K. Molecular analysis of congenital central hypoventilation syndrome. Hum Genet 2003; 114: 22-6.

17. Matera I, Bachetti T, Puppo F, Di Duca M, Morandi F, Casiraghi GM, Cilio MB, Hennekom R, Hofstra R, Schober JG, Ravazzolo R, Ottolino G, Ceccherini L. PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset central hypoventilation syndrome. J Med Genet 2004; 41: 373-80.

18. Bajaj R, Smith J, Trochet D, Pitkin J, Ouvrier R, Graf N, Silence D, Kluckow M. Congenital central hypoventilation syndrome and Hirschsprung’s disease in an extremely preterm infant. Pediatrics 2005; 115: e737-8.

19. Holzinger A, Mittal RA, Kachel W, Priessmann H, Hammel M, Ihrler S, Till H, Munch HG. A novel 17 bp deletion in the PHOX2B gene causes congenital central hypoventilation syndrome with total aganglionosis of the small and large intestine. Am J Med Genet A 2005; 139: 50-1.